Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy, the diabetes and obesity treatments, revealed data showing that its new weight-loss drug candidate ...

New trial data showed CagriSema led to 'superior' weight loss, but at a rate less than expectations Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy ...

Supermarkets are selling more eggs. Gyms are getting rid of cardio machines to make more room for free weights. And cosmetic clinics are seeing a lot of “Ozempic face”. It’s estimated about ...

Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street for the second time. The pharmaceutical giant, known for its blockbuster ...

GDANSK/LONDON (Reuters) - Bank of America analysts on Friday said Novo Nordisk (NYSE:NVO) may miss first-quarter expectations, as sales of its blockbuster Wegovy and Ozempic drugs lag, which could ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

GDANSK/LONDON (Reuters) - Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy and Ozempic drugs lag, which could prompt the ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year partnership with CordenPharma, a leading contract manufacturing firm. The deal ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like Ozempic and Mounjaro. That gamble has now collapsed. The Food ...